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Abstract
Background and Objectives—Electronic cigarettes (e-cigarettes) are a recent technology that 
has gained rapid acceptance. Still, little is known about them in terms of safety and effectiveness. 
A basic question is how effectively they deliver nicotine, however the literature is surprisingly 
unclear on this point. Here, a population pharmacokinetic (PK) model was developed for nicotine 
and its major metabolite cotinine with the aim to provide a reliable framework for the simulation 
of nicotine and cotinine concentrations over time, based solely on inhalation airflow recordings 
and individual covariates (i.e. weight and breath carbon monoxide CO levels).
Methods—This study included 10 adults self-identified as heavy smokers (at least one pack per 
day). Plasma nicotine and cotinine concentrations were measured at regular 10-minute intervals 
for 90 minutes while human subjects inhaled nicotine vapor from a modified e-cigarette. Airflow 
measurements were recorded every 200 milliseconds throughout the session. A population PK 
model for nicotine and cotinine was developed based on previously published PK parameters and 
the airflow recordings. All the analyses were performed with the nonlinear mixed-effect modelling 
software NONMEM 7.2.
Results—The results show that e-cigarettes deliver nicotine effectively, although the 
pharmacokinetic profiles are lower than those achieved with regular cigarettes. Our PK model 
effectively predicts plasma nicotine and cotinine concentrations from the inhalation volume, and 
initial breath CO.
Conclusion—E-cigarettes are effective at delivering nicotine. This new PK model of e-cigarette 
usage might be used for pharmacodynamic analysis where the PK profiles are not available.
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1 Introduction
The pharmacokinetics of nicotine and cotinine are well characterized in humans [1-3]. In 
1992 Robinson et al. published a reliable physiologically based pharmacokinetic (PBPK) 
model describing the disposition kinetics of nicotine and its major metabolite, cotinine, in 
humans (1). Very recently, Teeguarden et al. published a multi-route model of nicotine–
cotinine pharmacokinetics also in humans[2]. They also developed a PBPK model of 
nicotine and cotinine in humans after administration via i.v., oral and also inhalation routes 
using cigarettes (nicotine yield, 1.3 mg). Since the most common administration route for 
nicotine is inhalation, a focus on i.v. and oral administration route pharmacokinetics analysis 
might be limited.
The use of electronic cigarettes (e-cigarettes) has increased dramatically over the past few 
years, leading to a host of legal and regulatory issues over how to classify electronic 
cigarettes. An e-cigarette is a battery powered device which simulates tobacco smoking. 
These e-cigarettes generally use a small heating element that vaporizes a liquid solution 
containing the active ingredients, water, and propylene glycol or a similar solvent. The user 
simply inhales the resulting vapor in a process called “vaping”, an action similar to regular 
smoking but with electronic cigarette vapor. Some solutions contain a mixture of nicotine 
and flavorings, while others release a flavored vapor without nicotine. E-cigarette users 
generally perceive e-cigarettes to be effective at reducing nicotine cravings and also 
perceive them to be less harmful than regular cigarettes [4;5]. The benefits and risks of 
electronic cigarette use are uncertain as the technology is relatively new. While electronic 
cigarettes may be less harmful than regular cigarettes, they may still contain impurities and 
toxic ingredients [6]. There is some evidence that they are effective at delivering 
nicotine [7-9], as e-cigarettes lead to similar plasma cotinine elevations as regular 
cigarettes [10], although they may yield less nicotine per puff [11]. Users may need a period 
of weeks to learn how to use them to deliver the most nicotine. Individuals new to e-
cigarettes typically obtain lower plasma nicotine concentrations initially, but after four 
weeks of experience with e-cigarettes, they are able to achieve higher plasma nicotine 
concentrations and significantly greater overall nicotine intake [12]. However, the literature 
is ambiguous on how effectively e-cigarettes deliver nicotine to users, as some have reported 
no measurable increases in plasma nicotine following e-cigarette usage [13;14].The current 
study addresses how effectively e-cigarettes may deliver nicotine, and how well the delivery 
can be described with a PK model.
For the current study, a customized electronic cigarette was developed to allow precise 
measurements of the heated air temperature and time course of inhaled nicotine vapor 
volume. This allowed for precise control of and measurement of the nicotine vapor 
delivered. The developed electronic cigarette device is also compatible with magnetic 
resonance imaging (MRI) to allow direct functional neuroimaging during electronic 
cigarette usage in future studies. This allows for the direct measurement of brain activity 
while subjects make decisions about using nicotine as an addictive drug. First however, it is 
necessary to characterize the nicotine delivery resulting from inhalation from electronic 
cigarettes and the custom device described in this paper specifically. It should be noted that 
this custom e-cigarette was designed to be MR-compatible, and although it provides the 
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same functionality as open market e-cigarettes, we did not explicitly compare its 
performance to available e-cigarettes (see Limitations).
In this work, a population PK model for nicotine and its major metabolite, cotinine was 
developed, based on the airflow recordings of e-cigarettes, the loading dose for the e-
cigarette, the individual covariates, and on the nicotine and cotinine PK parameters 
published by Robinson et al. [3]. The purpose of this model was to provide a framework for 
the simulation of nicotine and cotinine concentrations over time, based solely on airflow 
recordings and individual covariates (i.e. weight and initial CO levels). To the best of our 
knowledge, this is the first population PK model describing nicotine and cotinine exposure 
with the use of e-cigarettes. This model can be used for pharmacodynamic analysis where 
the PK profiles are not available (kinetic-pharmacodynamic, KPD).
2 Methods
2.1 Electronic nicotine delivery system: custom e-cigarette
A customized electronic nicotine delivery system, “custom e-cigarette” compatible with 
MRI was developed. The custom e-cigarette is contained in an approximately 12” long 
section of 2” diameter PVC tubing. Inside the tubing is a ceramic heater set to maintain a 
controlled temperature of 300 degrees Fahrenheit. The heated air is drawn over a small wad 
of nonferromagnetic metallic wool, which served to provide a matrix with a large surface 
area for the heated air to vaporize the nicotine liquid. The wool is also non-combustible at 
the temperatures used, which helps avoid a burnt smell that otherwise may occur in e-
cigarettes. The wool was loaded with 0.45 mL of 18mg/mL nicotine liquid (JC original 
smoke juice, Johnson Creek, ISO 9001:2008 certified). We chose a US-based smoke juice 
supplier to minimize concerns regarding the quality and purity of the smoke juice, and we 
used an external supplier so that we could provide a realistic e-cigarette experience. Nicotine 
is readily absorbed in liquid form through the skin, so the custom e-cigarette was never 
loaded with more than 0.45mL at a time in order to minimize the risk of nicotine overdose 
from accidental liquid contact or ingestion. The heated air vaporizes the liquid held in the 
metal wool, and the heated nicotine vapor then flows into a 12” long, ½” diameter clear 
plastic tube. At the other end of the tube there is a disposable oneway valve which is 
inserted into the subject's mouth. In this way subjects can inhale heated nicotine vapor. The 
exhaled breath is subsequently vacuumed from a facemask on the subject's face and then 
forced through a carbon filter to avoid filling the experiment room with nicotine vapor.
The air flow into the custom e-cigarette is measured and controlled by a Controller. The 
Controller maintained the ceramic heater at 300° F and included an air flow measuring 
device (Omega FMA1700/1800). Air flow measurements were sampled at 5Hz by an A-to-
D converter and stored in a host computer for further processing. The Controller also had a 
solenoid valve that allowed access to the custom e-cigarette to be enabled or disabled by a 
host computer, but this feature was not used in the current study as the device was kept open 
for ad libitum consumption.
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2.2 Study design
Subjects were included in the study if they self-identified as heavy smokers (at least one 
pack per day) and had no stated intention of trying to stop smoking. Subjects (N=10, 5 
females, ages 18 to 24, mean 20.3) gave informed consent to participate. All procedures 
were reviewed and approved by the Indiana University Institutional Review Board. Subjects 
were asked to abstain from smoking for six hours prior to the study. After providing 
informed consent, the subjects were then weighed. Their exhaled breath carbon monoxide 
was measured (Smokerlyzer piCO, Covita) in parts per million. This measurement provided 
some information about how recently they had likely smoked and how much. More 
importantly, it also allowed us the option to screen out subjects who had recently smoked 
substantially and were therefore not likely to desire significant additional nicotine at the 
time [15]. The fact that subjects knew we would perform an initial CO screen provided 
additional incentive for them to abstain from cigarettes prior to the session. In practice, no 
subjects were excluded for excessive exhaled CO. After the CO measurement, study 
subjects were seated comfortably and then given an IV saline lock cannula by a registered 
nurse. The nurse drew 4 mL of blood at the start of the experiment and then again every 10 
minutes throughout the experiment, for a total of ten blood draws throughout the ninety 
minute session. Subjects were instructed to sit comfortably and inhale ad libitum for the 
duration. In some cases, if subjects noted that the vapor seemed to be depleted of nicotine, 
an additional amount of nicotine liquid was added to the custom e-cigarette. After the 
procedure, the blood samples were spun down for ten minutes, and the plasma was pipetted 
off and stored at −20 degrees Celsius. Four additional subjects completed the study but 
could not be analyzed due to equipment malfunction, leaving ten subjects reported in the 
analyses below.
2.3 Mass spectroscopy analysis
Nicotine, (+/−) cotinine, trans-3’-OH cotinine, and (S)cotinine N-oxide were quantified in 
plasma using phenacetin as the internal standard, liquid-liquid extraction, and HPLC-
MS/MS (API3200, Applied Biosystems). Separation of all analytes was performed with 
gradient HPLC (acetonitrile:10 mM ammonium acetate, pH=5.0) using a CN column (Luna, 
5 μm, 4.6 X 150 mm). The mass spectrometer was run in positive mode and the Q1/Q3 
settings for each analyte were 163/130, 177/80, 193/80, 193/96 and 180/65 for nicotine, 
cotinine, trans-3’-OH cotinine, cotinine-N-oxide, and phenacetin, respectively. In total, 560 
concentrations were measured (140 x 4 analytes). The limit of quantification (LOQ) is 0.1 
ng/mL for both compounds: 32 measurements below the LOQ (5.71% ).
2.4 Data analysis
All analyses were performed using NONMEM version 7.2 (Icon Development Solutions, 
Hanover, Maryland). Data below the limit of quantification (BLQ) were reported for both 
nicotine and metabolite at 0.1 ng/mL (see Mass spectroscopy analysis section for more 
details). BLQ values were included in the analyses and treated as censored information 
using the M3 method [18]. With the M3 method, the BQL observations in particular are 
taken to be the likelihoods that these observations are indeed below the limit. The Laplacian 
numerical estimation method was used for parameter estimation. Nicotine and cotinine 
de Mendizábal et al. Page 4
Clin Pharmacokinet. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
concentrations were simultaneously described. Due to the specific study design, some of the 
PK parameters were fixed to literature values. Inter-subject variability (ISV) was modeled 
using exponential functions. An additive model was used to describe residual variability for 
log-transformed data. This is consistent with a proportional error on the linear scale. Other 
residual error structures were also evaluated (e.g. combined error).
2.4.1 Dose and airflow—Inhaled nicotine is assumed to enter lung blood instantaneously, 
consistent with experimental data showing rapid uptake via inhalation [16;17]. The amount of 
nicotine that reaches the systemic circulation is assumed to be proportional to the airflow 
recordings. The inhaled airflow was recorded every 200 milliseconds throughout the 90 
minute session, even when the subject was not actively inhaling. Therefore, the airflow 
recordings were processed as follows: (i) Every negative value was transformed to zero; (ii) 
the 97.5th percentile of the airflow values was calculated based on all subjects (0.4 mL/min); 
(iii) Every value below this threshold was transformed to zero, implying no drug input at 
those times. The selection of the 97.5th percentile was based on the empirical distribution 
function of the airflows (no negative values) (supplementary material, online resource 1) 
with the aim to ensure the identification of the dose events (the patient is inhaling nicotine 
vapor) and to reduce the noise in the inputs. The dose events were defined based on this 
processed airflow (airflowP), the custom e-cigarette loading dose (LD - 18mg/mL) and a 
scaling factor (F) as follows:
(eq. 1)
The parameter F is a scaling factor that links the airflow recoding and the loading dose with 
the actual drug amount that reaches the systemic circulation.
2.4.2 Pharmacokinetic modeling—The population PK model for nicotine and its major 
metabolite cotinine developed in this analysis is based on the physiologically based 
pharmacokinetic (PBPK) model published by Robinson et al. [3] in 1992. This PBPK model 
accurately describes the disposition kinetics of nicotine and its major metabolite, cotinine, in 
human. Robinson et al. derived different rates and parameters from previously published 
human and animal data.Then, the PBPK model was tested comparing simulations of 
published studies, using similar dosing protocols to those reported. Total plasma clearances 
[CLT=CLH+CLR] and volumes of distribution for nicotine and cotinine (Vd) were then 
calculated from the PBPK ouput.
Due to the nature of the study design presented here, those model PK parameters were not 
directly estimable and were therefore fixed to the values reported by Robinson et al [3]: (i) 
Total plasma clearance (CLT = CLH + CLR) was fixed to 1.56 L/min for nicotine and 0.067 
L/min for cotinine; (ii) Nicotine hepatic clearance (CLH) was fixed to 1.09 L/min, where the 
80% goes to cotinine (CL2COT = 0.872 L/min)[19] and the rest to other metabolites 
(CL2METO = 0.218 L/min); (iii) total plasma clearance for cotinine was fixed to CLCOT = 
0.065 L/min (CLH=0.055 and CLR=0.010 L/min); (iv) Apparent volume of distribution 
(Vd) for nicotine and cotinine were fixed to 207 L and 73 L respectively based on the values 
reported by Robinson et al. [3]. All physiological parameters were based on population 
values for a 70-kg man. Both nicotine and cotinine pharmacokinetics were simultaneously 
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described with a one compartment linear model for each compound. Only the input 
parameters were estimated for this model based on the inhalation rates shown in equation 1.
2.4.3 CO levels: Covariate analysis—Exhaled carbon monoxide (CO, in parts per 
million) is a biomarker of recent smoking history [15] that might impact the nicotine and 
cotinine pharmacokinetic profiles. The potential effect of this covariate was evaluated in all 
model parameters. As expected, higher exhaled CO concentration was associated with 
higher initial concentrations for nicotine and cotinine. Linear and nonlinear models were 
explored connecting the initial concentrations for nicotine and cotinine based on the CO 
measurements. The selected models are shown in equation 2 for nicotine and in equation 3 
for its major metabolite:
(eq. 2)
(eq. 3)
where CO is the individual level of carbon monoxide, θNIC and θCOT are the initial 
concentrations for nicotine and cotinine respectively in absence of CO, and γNIC and γCOT 
the nonlinear factors.
2.4.4 Model selection criteria and evaluation—The minimum value of the objective 
function (OFV) provided by NONMEM, which corresponds approximately to −2 
×log(likelihood) [−2LL], served as a criteria for model comparison during the model 
development process. A decrease in −2LL of 6.63 points for one additional parameter, was 
regarded as a significant model improvement corresponding to a p-value of 0.01 for nested 
models. The Akaike information criteria (AIC), calculated as AIC=−2LL+2×NP, where NP 
is the number of parameter in the model, was used for selection among non-nested 
models [20]. The choice of the final model was based also on the OFV value, the precision of 
parameter estimates, goodness-of-fit plots and individual visual predictive checks (IVPCs). 
Precision of parameter estimates expressed as the 5th and 95th percentiles of the parameter 
distribution were computed from the analysis of 300 bootstrap data sets (sampling with 
replacement). The bootstrap analysis was performed using Perl-speaks-NONMEM [21]. 
Model parameter estimates were presented together (Table 1) with the corresponding 
relative standard error RSE(%), as a measure of parameter imprecision computed from the 
results of the bootstrap analysis. The degree of inter-subject variability (ISV) was expressed 
as a coefficient of variation CV(%). Inspection of goodness-of-fit plots included conditional 
weighted residuals (CWRES) and normalized prediction distribution errors (NPDE) [22;23]. 
Model performance was evaluated with individual visual predictive checks (IVPC): For 
every subject, based on the airflow and specific individual measurements (e.g. weight and 
level of CO), two hundred virtual individuals were simulated. At each time-point the 2.5, 50 
and 97.5th percentiles were calculated in every simulated study for nicotine and cotinine 
concentrations. Then, the 95% prediction interval from the resultant percentiles was 
computed and represented over time together with the raw individual data. Predictive checks 
were performed using MATLAB environment (The Mathworks, MA, United States).
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3 Results
A customized electronic nicotine delivery system, “custom e-cigarette” compatible with 
MRI was developed (Figure 1). The airflow recordings were used in order to establish the 
nicotine dose events (Figure 2) (one individual example on the online resource 2). Prior to 
the model development, the data were explored in an attempt to evaluate the link between 
those recordings and the nicotine plasma concentrations. The visualization of the individual 
airflow patterns (Figure 3A) and the corresponding individual PK profiles of the parent 
compound (nicotine) (Figure 3B) indicated that the “custom e-cigarette” actually delivers 
nicotine. Individuals with higher number (and intensity) of dose events (inhalations) tend to 
have higher concentrations throughout the 90 minute duration of the study.
The structure of the selected model is shown in Figure 4. The meaning of the model 
parameters are shown in the legend. The corresponding NONMEM control stream for the 
selected model is shown in the supplementary material (Online Resource 3). Inter-subject 
variability (ISV) was found to be significant for the dose scaling factor F, the distribution 
volume in the central compartments for cotinine VM, and in the initial plasma concentrations 
for nicotine and cotinine NIC0 and COT0 respectively (Table 1). η-shrinkage (%) was 1.14 
(F), 6.55 (Vm), 3.87 (NIC0) and 4.03 (COT0). The inclusion of a positive correlation 
between the BSV associated to the initial nicotine and cotinine concentrations significantly 
improved the OFV provided by NONMEM, as well as the visual model fitting. Part of the 
variability associated to these two parameters was explained by the measured levels of 
carbon monoxide (CO) at the beginning of the experiment. This reinforces the CO 
measurement as a very informative biomarker of recent smoking history. The weight of the 
individuals was also evaluated for correlation with the PK parameters but did not improve 
the model predictions. No other covariates were explored. Model parameter estimates are 
presented in Table 1 with the corresponding RSE%.
Individual and population model predictions as well as the empirical data are shown in 
figure 5. Figure 6 displays the goodness of fit plots for nicotine and cotinine, indicating that 
the selected model reasonably describes the observations. Observations were compared with 
the population model predictions (figure 6, left) as well as with individual predictions (figure 
6, center). No dose bias and misspecifications were observed. Evaluation of the NPDE did 
not show any tendency or model misspecification either (figure 6, right).
Model performance was also evaluated with individual visual predictive checks (IVPC) 
(Figure 7); based on the individual airflow time series, and on the corresponding individual 
CO levels, the 95% predicted interval was calculated for nicotine and cotinine plasma 
concentrations.
4 Discussion
Efficacy
Our results demonstrate that electronic cigarettes provide effective and measurable nicotine 
delivery, and that the subsequent nicotine pharmacokinetics and metabolism can be 
accounted for by existing models. Furthermore, with a sufficiently strong nicotine 
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concentration in the liquid “smoke juice” loaded into the e-cigarette, the plasma nicotine 
reaches lower but still comparable levels to those resulting from conventional cigarette 
smoking (Figure 3). This demonstration of effective nicotine delivery by e-cigarettes stands 
in contrast with earlier report[13;14], but is consistent with more recent report showing 
effectiveness at increasing plasma nicotine [8;9], and also with other reports showing 
increased plasma cotinine as a result of e-cigarette use [10][11]. The present results are also 
consistent with self-reported effectiveness at reducing nicotine cravings [4;5].
Accuracy
Besides demonstrating the efficacy of e-cigarettes in terms of delivering nicotine, the model 
developed in this paper provides the first description of the concentration time profiles for 
nicotine and cotinine after inhalation from an electronic cigarette device. Thus, the model 
allows the plasma nicotine and cotinine levels to be predicted non-invasively. Furthermore, 
the developed model had well determined parameters as evidenced by the low RSE values 
and predicted individual concentration profiles well. The results are consistent with earlier 
modeling approaches to nicotine from cigarettes [3]. Nevertheless, the results should be 
replicated independently in order to increase confidence in the model.
A key technical aspect of being able to manage the 5Hz measurement frequency for the 
airflow was to filter what were apparent “noise” signals that represented most of the 
measurements over time. It was not likely that this very low flow rates (<0.4mL/min) would 
have contributed to the overall observed concentration and their inclusion would have made 
the modeling approach untenable. By filtering above the 97.5th percentile, key input events 
for nicotine inhalation/dose delivery were captured (see figures 1B and 1C).
The accuracy of the model depends on having a good estimate of the initial conditions of 
plasma concentrations. We explicitly measured the starting plasma concentrations, and we 
additionally measured exhaled CO as an additional (though limited) correlate of initial 
plasma concentrations. The exhaled CO is only useful as a predictor of recent cigarette 
smoking and would not be expected to correlate with recent e-cigarette usage, as these 
generate no significant CO. The CO is primarily utilized to predict the baseline 
concentrations and, at least statistically, significantly improved the description by the model 
of the baseline values. Thus, it is not the CO that is the target of interest but rather the 
impact on predicting the likely baseline nicotine level where this CO measure appears to be 
useful. Still, if e-cigarette airflow is measured for a sufficiently long period of time, the 
impact of the initial conditions (and associated inaccuracies) will diminish toward zero over 
time.
E-cigarettes
Many questions remain open regarding the safety and effectiveness of e-cigarettes, 
especially as aids to smoking cessation. Our results do not address whether e-cigarettes are 
safe for the public, although our very modest sample size revealed no immediate adverse 
events. Our results also do not indicate whether e-cigarettes are effective as an aid to 
smoking cessation. What our results do show as a first step however is that e-cigarettes can 
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be effective in delivering nicotine specifically in a way that is well-characterized by our 
pharmacokinetic model.
As e-cigarette use becomes more and more common, understanding associated nicotine 
delivery and both cognitive and addictive effects will become more important. This model 
represents a tool that can help to more precisely understand the relationship between the 
inhalation delivered nicotine dose and nicotine and cotinine plasma concentration levels. 
The plasma concentration levels can then be evaluated in the context of any number of target 
responses or toxicities.
Looking ahead, we are currently planning to use our custom electronic cigarette device to 
carry out functional neuroimaging studies of e-cigarette use. The present study provides a 
foundation for our planned functional neuroimaging, as our device is MR-compatible. In this 
way, it will be possible to predict plasma nicotine and cotinine concentrations in subjects 
without having to simultaneously draw blood. This non-invasive approach may be 
particularly helpful in experiments involving many interventions, where the action of a 
blood draw may skew patient responses in MRI based studies as well as increase the costs 
associated with the study. This first issue is particularly important when assessing the 
cognitive and addiction liability effects of nicotine inhalation using the MRI paradigm.
Limitations
The study has several limitations. Our custom e-cigarette was designed to be MR-
compatible, and as such, it may not be identical to e-cigarettes available on the open market. 
We did not directly compare our custom e-cigarette against commercial e-cigarettes. The 
commercial e-cigarettes may vary among brands in their effectiveness at delivering nicotine. 
Likewise, available smoke juice formulations may differ in composition and effective 
bioavailability. Thus, we have not shown that every available e-cigarette effectively delivers 
nicotine, and it is beyond the scope of the current study to do so. Also, we have not shown 
that every available e-cigarette smoke juice effectively delivers nicotine, as the effective 
bioavailability may vary as a function of solution pH and other ingredients in the smoke 
juice. The estimated value for the scaling factor F will have to be re-estimated if other e-
cigarettes are used, since it could vary among brands. Due to the data available and study 
design, other factors that might affect nicotine delivery have not been explored here.
Our study specifically showed that at least the present custom e-cigarette with an airflow 
temperature of 300° F over a non-combustible medium (metallic wool) and with the 
particular smoke juice can effectively deliver nicotine. Also, we have shown that the 
nicotine delivery can be accounted for with a PK model similar to one that is valid for 
regular cigarettes, as a function of inhaled e-cigarette vapor volume. Another potential 
limitation of the current study is that e-cigarette users become more proficient at using the e-
cigarette over time, so that they are able to increase their plasma nicotine levels more 
effectively after a few weeks of use. We did not control for the length of time subjects had 
used e-cigarettes. However, are recruitment criteria required that subjects be current heavy 
smokers with no stated intention of quitting. This means that our subjects were generally not 
e-cigarette users, and they would therefore be less proficient at increasing their plasma 
nicotine levels. The fact that we found measurable plasma nicotine increases suggests that 
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the relative lack of experience did not prevent them from obtaining nicotine from our 
custom e-cigarette. Furthermore, our detailed measurements of airflow account for any 
individual differences based on levels of experience with e-cigarettes. Finally, due to the 
limited sample size of the present study, the model we present here should be validated in an 
independent sample of subjects.
5 Conclusion
A well estimated population pharmacokinetic model for plasma concentrations of nicotine 
and cotinine after e-cigarette nicotine delivery was developed and will provide the basis for 
the determination of typical nicotine levels for any given pattern of e-cigarette associated 
airflow delivery of nicotine.
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Abbreviations
e-cigarette electronic cigarette
ISV inter- subject variability
NPDE normalized prediction distribution errors
RSE relative standard error
CV coefficient of variation
CO carbon monoxide
LOQ lower limit of quantification
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Key Points
• Electronic cigarettes (e-cigarettes) are rapidly gaining acceptance, but their 
pharmacokinetic effect with respect to nicotine is unclear.
• We measured initial carbon monoxide (CO) breath, e-cigarette inhalation 
airflow and plasma nicotine and cotinine concentrations for 90 minutes while 
human subjects are using the e-cigarette. Based on these data we developed a 
population PK model able to simultaneously describe nicotine and cotinine 
profiles in plasma.
• E-cigarettes deliver nicotine effectively, although the pharmacokinetic profiles 
are lower to those achieved with regular cigarettes. The model might be 
extremely useful for nicotine drug effect analysis and quantification when the 
actual PK profiles are not available.
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Figure 1. Diagram of custom e-cigarette apparatus
Air passed through a ceramic heater encased in 2” diameter PVC pipe, where it was heated 
to a controlled temperature of 300F. The heated air passed through a small orifice and over a 
½” diameter ball of non-ferromagnetic metallic wool, which was saturated with 0.45mL of 
smoke juice (Johnson Creek, nominal 18 mg/mL nicotine). The resulting heated vapor 
passed through a one-way check valve along a 12” section of flexible tubing and into the 
user's mouth. Inhaled airflow was measured in mL/min.
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Figure 2. A. Airflow: Raw data. B. Airflow: Processed data
The processing was developed in three consecutive steps: (i) Every negative value was 
transformed to zero; (ii) the 97.5th percentile was calculated based on all subjects; (iii) Every 
value below such percentile was transformed to zero. C. Airflow: Dose events. The dose 
events and their intensities were defined as processed airflow recordings bigger than zero 
(see methods for more details).
de Mendizábal et al. Page 14
Clin Pharmacokinet. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
A. Individual dose events identified from the airflow Every subplot corresponds a different 
individual. Circles represent the dose events, the individual is inhaling, based on the airflow 
measurements. B. Individual nicotine plasma concentrations. Circles are the observed 
nicotineconcentrations for every individual. Dashed lines are a linear interpolation between 
the observations. Solid black line shows the observed median kinetic for nicotine. Every 
color corresponds to a different individual. Same color code was used than for the individual 
dose events subplots, allowing the connection between airflow – dose events and the 
nicotine PK profiles.
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Figure 4. Structural pharmacokinetic model for nicotine and its major metabolite cotinine
Circles represent the central compartments for nicotine and cotinine. PK parameters: F, 
scaling factor for dose calculation and bioavailability; VC and VM are the volumes of 
distribution of the central compartment for nicotine and cotinine respectively, CL2COT and 
CL2METO are the formation rates for cotinine and other metabolites respectively; CLEX and 
CLCOT are the elimination rates for nicotine and cotinine.
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Figure 5. Individual predictions versus observations for nicotine (A) and cotinine (B)
The grey colors in (A) denote nicotine; and the light blue colors in (B) denote cotinine. 
Circles represent observations above the minimum quantification level. Squares represent 
observations below the quantification level. The red dashed lines represent the population 
prediction. The solid lines represent the individual predictions.
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Figure 6. 
Goodness of fit plots of the selected population PK model for (A) nicotine (grey) and (B) 
cotinine (light blue). PRED corresponds to the population model predictions, IPRED to the 
individual model predictions and NPDE the normalized prediction distribution errors. Solid 
lines show the identity lines for the first two columns and 0 line for the last column.
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Figure 7. Individual Visual Predictive Checks
Results from 200 simulated studies. Shaded areas represent the 95% prediction interval (PI) 
for every individual based on their airflow, CO levels and weight. The black lines 
correspond to the median of the simulated subjects. Points are the observations. The grey 
color stands for nicotine (A) and light blue for the major metabolite cotinine (B).
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